Literature DB >> 30918817

Discriminating performance of macular ganglion cell-inner plexiform layer thicknesses at different stages of glaucoma.

Melih Ustaoglu1,2, Nilgun Solmaz3, Feyza Onder3.   

Abstract

AIM: To determine the discriminating performance of the macular ganglion cell-inner plexiform layer (GC-IPL) parameters between all the consecutive stages of glaucoma (from healthy to moderate-to-severe glaucoma), and to compare it with the discriminating performances of the peripapillary retinal nerve fiber layer (RNFL) parameters and optic nerve head (ONH) parameters.
METHODS: Totally 147 eyes (40 healthy, 40 glaucoma suspects, 40 early glaucoma, and 27 moderate-to-severe glaucoma) of 133 subjects were included. Optical coherence tomography (OCT) was obtained using Cirrus HD-OCT 5000. The diagnostic performances of GC-IPL, RNFL, and ONH parameters were evaluated by determining the area under the curve (AUC) of the receiver operating characteristics.
RESULTS: All GC-IPL parameters discriminated glaucoma suspect patients from subjects with healthy eyes and moderate-to-severe glaucoma from early glaucoma patients (P<0.017, for all). Also, minimum, inferotemporal and inferonasal GC-IPL parameters discriminated early glaucoma patients from glaucoma suspects, whereas no RNFL or ONH parameter could discriminate between the two. The best parameters to discriminate glaucoma suspects from subjects with healthy eyes were superonasal GC-IPL, superior RNFL and average c/d ratio (AUC=0.746, 0.810 and 0.746, respectively). Discriminating performances of all the parameters for early glaucoma vs glaucoma suspect comparison were lower than that of the other consecutive group comparisons, with the best GC-IPL parameters being minimum and inferotemporal (AUC=0.669 and 0.662, respectively). Moreover, minimum GC-IPL, average RNFL, and rim area (AUC=0.900, 0.858, 0.768, respectively) were the best parameters for discriminating moderate-to-severe glaucoma patients from early glaucoma patients.
CONCLUSION: GC-IPL parameters can discriminate glaucoma suspect patients from subjects with healthy eyes, and also all the consecutive stages of glaucoma from each other (from glaucoma suspect to moderate-to-severe glaucoma). Further, the discriminating performance of GC-IPL thicknesses is comparable to that.

Entities:  

Keywords:  cirrus HD-OCT; ganglion cell-inner plexiform layer; glaucoma suspect; optic nerve head; retinal nerve fiber layer

Year:  2019        PMID: 30918817      PMCID: PMC6423388          DOI: 10.18240/ijo.2019.03.18

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  5 in total

1.  Foveal pit morphological changes in asymptomatic carriers of the G11778A mutation with Leber's hereditary optic neuropathy.

Authors:  Xin-Ting Liu; Mei-Xiao Shen; Chong Chen; Sheng-Hai Huang; Xi-Ran Zhuang; Qing-Kai Ma; Qi Chen; Fan Lu; Yi-Min Yuan
Journal:  Int J Ophthalmol       Date:  2020-05-18       Impact factor: 1.779

2.  Ganglion cells apoptosis in diabetic rats as early prediction of glaucoma: a study of Brn3b gene expression and association with change of quantity of NO, caspase-3, NF-κB, and TNF-α.

Authors:  Irwan Tjandra; Purnomo Soeharso; Widya Artini; Nurjati Chairani Siregar; Andi Arus Victor
Journal:  Int J Ophthalmol       Date:  2020-12-18       Impact factor: 1.779

Review 3.  Does Retinal Ganglion Cell Loss Precede Visual Field Loss in Glaucoma?

Authors:  Donald C Hood
Journal:  J Glaucoma       Date:  2019-11       Impact factor: 2.503

Review 4.  Macular imaging with optical coherence tomography in glaucoma.

Authors:  Vahid Mohammadzadeh; Nima Fatehi; Adeleh Yarmohammadi; Ji Woong Lee; Farideh Sharifipour; Ramin Daneshvar; Joseph Caprioli; Kouros Nouri-Mahdavi
Journal:  Surv Ophthalmol       Date:  2020-03-19       Impact factor: 6.048

5.  Determinants of macular ganglion cell-inner plexiform layer thickness in normal Chinese adults.

Authors:  Xiaoyu Xu; Hui Xiao; Kunbei Lai; Xinxing Guo; Jingyi Luo; Xing Liu
Journal:  BMC Ophthalmol       Date:  2021-06-29       Impact factor: 2.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.